PharmaValu brings pharmaceuticals and value into one concise identity. An educational publication could explain medicine pricing, who pays and how outcomes enter the value discussion. That gives a future brand a focused subject and a reason for readers to return. PharmaValu.com is held for development and acquisition consideration.
The name points at the word value, and that is the editorial stance. Many sources already list prices or promote savings. Fewer explain the reasoning that connects a price to evidence about outcomes, or why reasonable people disagree about that connection. PharmaValu would occupy that explanatory middle ground.
The intended readers are people who encounter drug pricing in their work or lives without being specialists: journalists covering health budgets, employee benefits staff reading pharmacy reports, students in public health or economics, policy staff, and patients or caregivers trying to understand why a bill looks the way it does. What they share is a need for plain explanations of terms like list price, rebate, formulary tier and cost-effectiveness threshold, without sales pressure and without anyone telling them which medicine to take.
02
Explainers on the pricing chain
One core application is a set of explainers that trace a medicine from manufacturer to patient: how list prices are set, where wholesalers, pharmacies and pharmacy benefit managers sit, why rebates create a gap between list and net price, and why two people with different coverage can pay very different amounts for the same prescription. Each piece would describe mechanisms rather than claim specific prices, and would note how arrangements vary by country and payer.
03
A guide to value assessment methods
A second application is an accessible guide to how health systems judge whether a medicine's price is justified. That includes health technology assessment, comparative effectiveness, quality-adjusted life years, budget impact analysis and the debates around each. The aim is to help readers understand what these methods measure, what assumptions they rest on, and what they leave out, so that published assessments can be read critically rather than taken as verdicts.
04
Glossary and reading guides
A third application is a reference glossary and short guides to reading primary documents: how to interpret a formulary, what a reimbursement decision summary typically contains, and which questions to ask of a cost study. These resources would explain, not evaluate, any particular product, and would carry clear notes that they are general education rather than medical, legal or financial advice.
Perspective
A practical guide to price, cost and value in medicines
When people say a medicine is expensive, they may mean its list price, what they personally paid, what their insurer spent, or that its cost seems out of proportion to its benefit. These are different claims. This guide sets out the main distinctions, walks through a hypothetical example, and offers questions for reading any pricing or value claim more carefully.
